Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Tocilizumab vs Tocilizumab in Methotrexate-Inadequate Response Rheumatoid Arthritis
2008-005525-11Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Rituximab + Tocilizumab + Methotrexate with Tocilizumab + Methotrexate + Placebo (2 arms). Primary endpoint: Proportion of patients with low disease activity at week 16. Started Dec 2008; status: completed.
02
Drugs
rituximabtocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-005525-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005525-11.